Why One-Time Aneurysm Screening Targets Older Men Who Ever Smoked

The narrow target is deliberate, not an oversight. The US Preventive Services Task Force gives a grade B to one-time ultrasound screening for abdominal aortic aneurysm (AAA) only in men aged 65 to 75 who have ever smoked, because that is the single population where four large randomized trials actually measured a benefit that outweighed the harms. Women and men who never smoked land on weaker statements not because their arteries are immune, but because the evidence that screening changes their outcomes is either thinner or points the other way. Reading the 2019 recommendation closely shows how a grade letter gets fixed to one specific risk group.

What the grade letters are actually saying

The Task Force does not grade a disease. It grades the certainty and the size of net benefit for a defined population receiving a defined test. A grade B means moderate certainty that the net benefit is moderate. A grade C means moderate certainty that the net benefit is small, so the service should be offered selectively rather than routinely. A grade D means moderate certainty that the harms outweigh the benefits, a recommendation against. A grade I means the evidence is simply insufficient to weigh benefits against harms at all. Those four verdicts, published in JAMA in December 2019, map onto four different groups of older adults, and the reason they differ lives in the trial data.

The trials studied almost only one group

The recommendation rests on four large randomized controlled trials: MASS, Viborg County, Chichester, and Western Australia. Their combined enrollment runs into the tens of thousands, but as the Task Force notes plainly, the randomized evidence focuses almost entirely on men aged 65 to 75. Pooled across those trials, inviting men to screening produced a statistically significant 35 percent reduction in AAA-related mortality. The number needed to screen to prevent one aneurysm death was roughly 305 men. That is a real, measurable payoff.

Two caveats sit alongside it. First, the pooled analysis showed no effect on all-cause mortality, which means screening shifts the cause of death statistics more clearly than it shifts the odds of dying overall. Second, the benefit concentrates in smokers. The recommendation describes smoking as the strongest predictor of AAA prevalence, growth, and rupture, with a dose-response pattern: more smoking exposure, more risk. An AAA is defined as an aortic diameter of 3.0 cm or larger, and the recommendation notes the risk of death with rupture runs as high as 81 percent. When a lethal event is that concentrated in one exposure group, screening that group is where the arithmetic works.

Why never-smoking men slide to a grade C

Men aged 65 to 75 who never smoked can still form an aneurysm, but their baseline prevalence is lower, and lower prevalence shrinks the absolute benefit of finding disease early. Population studies in older men put AAA prevalence somewhere between 1.2 and 3.3 percent, and because smoking is the dominant risk factor, never-smokers fall toward the lower end of that spread. The test itself is excellent: one-time ultrasonography carries 94 to 100 percent sensitivity and 98 to 100 percent specificity. The limiting factor is not the ultrasound. It is that in a low-prevalence group the same test finds fewer true aneurysms per thousand scans while the harms stay constant. That is why never-smoking men get a grade C and a recommendation to decide selectively, weighing individual factors such as family history, rather than a blanket yes.

Why women land on D or I

Women are not one category here, and the split is instructive. Women who never smoked and have no family history receive a grade D, an active recommendation against routine screening. The reason is that AAA is markedly less common in women in this profile, so the harms of screening a low-risk population outweigh the small chance of benefit. The Chichester trial, the one trial that enrolled women, found AAA prevalence of roughly 1.3 percent in women versus 7.6 percent in men.

Women who ever smoked or who have a family history of AAA receive a grade I, insufficient evidence. This is an honest admission rather than a judgment. The trials were built around men, so there is no adequately powered randomized data to tell us whether screening higher-risk women helps or harms. The biology may not transfer cleanly either. The recommendation notes that in women aneurysms tend to rupture at smaller diameters and at older ages than in men, and that operative mortality after repair ran higher in women. Because the surgical thresholds that guide repair were derived largely from male data, a program built to the male pattern could leave higher-risk women under-treated at the diameters where they actually rupture while still exposing them to the harms of intervention. The trials were simply not built to settle that question.

The harms half of the ledger

None of this makes sense without the other side of the balance. Screening everyone would sound safer only if the test were free of consequences, and it is not. Finding an aneurysm sets off surveillance, anxiety, and sometimes surgery. The trials showed roughly 40 percent more elective operations in the screened groups, and elective aneurysm repair carries its own operative risk. Overdiagnosis of small aneurysms that would never have ruptured, and the overtreatment that can follow, are the reason the Task Force refuses to screen populations where the true-positive yield is low. A grade B for high-risk men and a grade D for low-risk women are two applications of the same rule: screen where the benefit clears the harm, and decline where it does not.

Read this way, the recommendation is less a statement about who deserves attention and more a map of where the evidence is strong, weak, or missing. It is educational, not medical advice, and individual decisions belong in a conversation with a clinician who knows the person's history.